AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JUL 4 - (NewsRx.com & NewsRx.net) -- The U.S. Food and Drug Administration (FDA) has approved a new 35 mg once-a-week dosage strength for Actonel (risedronate sodium tablets) for the prevention and treatment of postmenopausal osteoporosis. It will be available in mid-June 2002, by prescription only.
Robert Lindsay, MD, PhD, chief of internal medicine at Helen Hayes Hospital, Professor of Clinical Medicine, Columbia University, and principal investigator of the Actonel once-a-week approval study, stated that patients and doctors always welcome effective new treatment choices, and now there is data showing that once-a-week dosing of Actonel is therapeutically equivalent to daily 5 mg dosing.
The FDA based its approval on safety and efficacy data from a one-year, double-blind, multicenter study that included 1456 postmenopausal women with osteoporosis and compared the effects of the once-a-week and daily dosing of Actonel on bone mineral density (BMD). Patients taking Actonel 35 mg once-a-week experienced a ...